BDBM444543 US10662186, Compound 63::US10988476, Compound I-63

SMILES CC(C)n1c(C)nc2c(F)cc(cc12)-c1nc(Nc2ccc3CN(CCN(C)C)CCc3n2)ncc1F

InChI Key InChIKey=KGMVZSJAPXYTKH-UHFFFAOYSA-N

Data  46 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 46 hits for monomerid = 444543   

TargetCyclin-dependent kinase 1(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 143nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetRAC-alpha serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of AKT1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 30nMAssay Description:Inhibition of CDK9/cyclinT1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetPlatelet-derived growth factor receptor beta(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 392nMAssay Description:Inhibition of PDGFRbeta (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetAurora kinase A(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of AURA (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetRAF proto-oncogene serine/threonine-protein kinase(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 2.79E+4nMAssay Description:Inhibition of cRAF (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetMitogen-activated protein kinase 3(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 1.35E+4nMAssay Description:Inhibition of ERK1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetSerine/threonine-protein kinase Chk1(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 9.18E+3nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human ERG expressed in CHO cells at - 80 mV holding potential by Q-patch clamp electrophysiology assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 4(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 1.12nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 2nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 47.7nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 787nMAssay Description:Inhibition of JAK1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 5(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 33.6nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 261nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 30.3nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 1.12nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 2nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 47.7nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 1(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 143nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 5(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 33.6nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 7(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 261nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 9(Human)
Shanghai Pharmaceuticals Holding

US Patent
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 30.3nMAssay Description:1. Take 10 mM stock solution of the test compound, in 96-well compound plate, DMSO was used to dilute the compound to an initial concentration of 100...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/1/2021
Entry Details
Go to US Patent

TargetAurora kinase B(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 8.58E+3nMAssay Description:Inhibition of AURB (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 143nMAssay Description:Inhibition of CDK1/cyclin B (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 170nMAssay Description:Inhibition of JAK2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetSerine/threonine-protein kinase pim-2(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 177nMAssay Description:Inhibition of PIM2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 64nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 5 activator 1(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 98nMAssay Description:Inhibition of CDK5/p25 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 1.22E+3nMAssay Description:Inhibition of CDK7/cyclinH/MAT1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 1.97E+3nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetPlatelet-derived growth factor receptor alpha(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 970nMAssay Description:Inhibition of PDGFRalpha (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 1.05E+3nMAssay Description:Inhibition of SRC (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetVascular endothelial growth factor receptor 2(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 3.93E+3nMAssay Description:Inhibition of KDR (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetMitogen-activated protein kinase 8(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 4.17E+3nMAssay Description:Inhibition of JNK1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetSerine/threonine-protein kinase Chk2(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 978nMAssay Description:Inhibition of CHK2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetMitogen-activated protein kinase 9(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 305nMAssay Description:Inhibition of JNK2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 0.710nMAssay Description:Inhibition of recombinant human full length N-terminal GST-tagged CDK4 (1 to 303 residues)/cyclin D3 (1 to 292 residues) expressed in baculovirus exp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetMitogen-activated protein kinase 10(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 416nMAssay Description:Inhibition of JNK3 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetSerine/threonine-protein kinase B-raf(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 8.29E+3nMAssay Description:Inhibition of BRAF (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetHigh affinity nerve growth factor receptor(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 110nMAssay Description:Inhibition of TRK-A (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetMAP kinase-activated protein kinase 2(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of MAPKAPK2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetFibroblast growth factor receptor 1(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of FGFR1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
Target5'-AMP-activated protein kinase catalytic subunit alpha-1(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 865nMAssay Description:Inhibition of AMPKa1 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D3(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant human full length N-terminal GST-tagged CDK6 (1 to 326 residues)/cyclin D3 (1 to 292 residues) expressed in baculovirus exp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Shanghai Pharmaceuticals Holding

Curated by ChEMBL
LigandPNGBDBM444543(US10662186, Compound 63 | US10988476, Compound I-6...)
Affinity DataIC50: 53nMAssay Description:Inhibition of recombinant human full length N-terminal GST-tagged CDK2 (1 to 298 residues)/cyclin A2 (1 to 432 residues) expressed in baculovirus exp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/17/2021
Entry Details Article
PubMed